Social media

The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...

PubsHub Journals & Congresses now includes publication AI policy guidelines, ensuring ethical use and transparency in research. Whether you use AI to analyze data or draft manuscripts, learn what’s required for complianc...

ICON is heading to SCOPE 2026 From labs and patient solutions to site strategies and biosimilars, our experts will be on the ground in Orlando from 2–5 February. We’re ready to share insights on accelerating clinical de...

To unlock the full value of emerging multi-indication therapies, developers must adopt strategies that prioritise early cross-functional planning and innovative trial architecture. ICON’s Jack Martin and Alan Baldridge...

Product labelling and promotional materials are the foundation of pharma communication and effective pharmaceutical communications begin with a strategic vision anchored in the product label. Regulatory change often br...

#OCTWestCoast will be returning to Burlingame for the 18th annual event on 11-12 February. Pass by booth \#79 and engage in an insightful discussion with ICON Biotech’s professionals regarding the latest challenges and s...

In 2025 ICON was independently recognised as a leading CRO for both Ph1 and Ph 2/3 studies and was also awarded Best CRO in APAC. Learn more. https://ow.ly/wfMb50XSPQG

Clinical trials rely on strong collaboration across multiple roles, each with a clearly defined remit. Yet the distinction between Clinical Research Associates, Clinical Trial Assistants, and Site Management Associates i...

ICON is honoured to be recognised on TIME and Statista’s World’s Best Companies of 2025 list for the third consecutive year. This achievement is a testament to our people, our values, and our vision for a better future. ...

We’re celebrating a major milestone. ICON has been named one of TIME and Statista’s World’s Best Companies of 2025 — for the third year in a row. This recognition is all about our people, our purpose and our passion. Tha...

Demographic Matching in Organ Impairment Studies: Why It Matters Organ impairment (OI) studies are critical for safe and effective drug development—but did you know that demographic matching can make or break the accurac...

While RWD and tokenisation introduce many efficiencies and benefits to long-term follow-up, there are also extremely stringent requirements for handling the associated data. Find out how to ensure secure long-term foll...